The legal action centers on claims that Zynex shipped products far exceeding actual demand, artificially boosting revenue figures in the process. According to the complaint, these practices triggered scrutiny from insurers such as Tricare regarding the submission of false claims. This oversight allegedly exposed the company to significant risks, including potential removal from insurance networks and federal penalties that were never disclosed to the public.
In section Releases
Kuehn Law Launches Investigation into Zynex Over Revenue Practices
Shareholders of Zynex, Inc. are under scrutiny as Kuehn Law, PLLC investigates potential breaches of fiduciary duty by company leadership. The probe follows a federal securities lawsuit alleging that the medical device firm misled investors through inflated revenue reporting and the improper distribution of products like electrodes.
Investors who purchased ZYXI stock prior to March 13, 2023, are being urged to contact attorney Sophia Anne Silayan to discuss their legal options. Kuehn Law has stated it will cover all case costs, operating on a contingency basis for those joining the litigation. With the window to enforce shareholder rights potentially closing, the firm is encouraging immediate outreach to assess individual claims.
Comments (0)
No comments yet. Be the first!